The Widespread Impact of Mammalian MicroRNAs on mRNA Repression and Evolution
By Kyle Kai-How Farh, Andrew Grimson, Calvin H. Jan, Benjamin P. Lewis, W. K. Johnston, Lee P. Lim, C. Burge, David P. Bartel. Science, 2005
1,490 citations recorded by the source corpus.
Subfields: Cancer Research, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/a338877a6c9e8a0f4efc90bbfb10ac6ef5895d96
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
- David P. Bartel
- Carlo Maria Croce
- George A. Calin
- Nikolaus Rajewsky
- Phillip A. Sharp
- E. Miska
- Frank J. Slack
- Eugene Berezikov
In Molecular Biology
- David P. Bartel
- Carlo Maria Croce
- John S. Mattick
- Nikolaus Rajewsky
- Phillip A. Sharp
- Phillip D. Zamore
- Richard A. Young
- George A. Calin
Citations in the corpus
- Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. (2009, background): “Such a function fits the widely assumed role of miRNAs as effectors acting in a context-dependent, combinatorial manner (19, 26).”
- Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth (2008, background): “Through base-pairing with its targeted mRNAs, a miRNA induces RNA degradation or translational suppression of the targeted transcripts [9,10].”
- Small non-coding RNAs in animal development (2008, background): “Global analysis of mRNA levels relative to miRNAs shows low or undetectable levels of expression of predicted target mRNAs in tissues that express the targeting miRN”
- miR-19 is a key oncogenic component of mir-17-92. (2009, neutral): “1B; Lewis et al. 2003, 2005; Farh et al. 2005; Grimson et al. 2007).”
- Control of Embryonic Stem Cell State (2011, background): “, 2006), and this miRNA family also promotes the clearance of transcripts in early mammalian development (Farh et al., 2005).”
- Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “In many cases, target mRNA levels diminish but do not disappear (Farh et al., 2005; Lim et al., 2005).”
- Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. (2006, background): “The ability of siRNAs to regulate large numbers of transcripts is similar to the regulation of large numbers of transcripts by miRNAs (Lewis et al. 2003; Stark et al. 2003; Brennecke et al. 2005; Farh et al. 2005; Grun et al. 2005; Krek et al. 2005; Lim et al. 2005; Xie et al. 2005) Intended and uni”
- MicroRNA targeting specificity in mammals: determinants beyond seed pairing. (2007, methodology): “site-conservation analysis, expression arrays, and sitedepletion analysis (Farh et al., 2005; Lewis et al., 2005; Lim et al., 2005).”
- MicroRNAs can generate thresholds in target gene expression (2011, neutral): “During a developmental transition where a tissue-specific miRNA is upregulated and its pool of target genes are downregulated, a trend that has been reported in fruitflies and in mammal”
- MicroRNAs in development and disease. (2011, methodology): “It should be noted that nonconserved miRNAs-targeted sites respond equally well to inhibition by miRNAs (170).”
- MicroRNAs accurately identify cancer tissue origin (2008, neutral): “MiRNAs have emerged as highly tissue-specific biomarker”
- MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype (2007, background): “We could detect only a few instances of enrichment for down- or upregulation of predicted target mRNAs consistent with changes in miRNA expression, although previous studies of normal human tissue did observe such an enrichment [ 45 ,99].”